BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20484813)

  • 1. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.
    Freigang S; Zadorozhny V; McKinney MK; Krebs P; Herro R; Pawlak J; Kain L; Schrantz N; Masuda K; Liu Y; Savage PB; Bendelac A; Cravatt BF; Teyton L
    J Clin Invest; 2010 Jun; 120(6):1873-84. PubMed ID: 20484813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scavenger receptors target glycolipids for natural killer T cell activation.
    Freigang S; Landais E; Zadorozhny V; Kain L; Yoshida K; Liu Y; Deng S; Palinski W; Savage PB; Bendelac A; Teyton L
    J Clin Invest; 2012 Nov; 122(11):3943-54. PubMed ID: 23064364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of bovine CD1d reveal altered αGalCer presentation and a restricted A' pocket unable to bind long-chain glycolipids.
    Wang J; Guillaume J; Pauwels N; Van Calenbergh S; Van Rhijn I; Zajonc DM
    PLoS One; 2012; 7(10):e47989. PubMed ID: 23110152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
    Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
    Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
    Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
    J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
    Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
    J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells.
    Sullivan BA; Nagarajan NA; Wingender G; Wang J; Scott I; Tsuji M; Franck RW; Porcelli SA; Zajonc DM; Kronenberg M
    J Immunol; 2010 Jan; 184(1):141-53. PubMed ID: 19949076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.
    Im JS; Arora P; Bricard G; Molano A; Venkataswamy MM; Baine I; Jerud ES; Goldberg MF; Baena A; Yu KO; Ndonye RM; Howell AR; Yuan W; Cresswell P; Chang YT; Illarionov PA; Besra GS; Porcelli SA
    Immunity; 2009 Jun; 30(6):888-98. PubMed ID: 19538930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing NKT cell ligands as vaccine adjuvants.
    Carreño LJ; Kharkwal SS; Porcelli SA
    Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between carbohydrate and lipid in recognition of glycolipid antigens by natural killer T cells.
    Pei B; Vela JL; Zajonc D; Kronenberg M
    Ann N Y Acad Sci; 2012 Apr; 1253(1):68-79. PubMed ID: 22352829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
    Kharkwal SS; Arora P; Porcelli SA
    Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
    Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
    J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKT cell activation by local α-galactosylceramide administration decreases susceptibility to HSV-2 infection.
    Iversen MB; Jensen SK; Hansen AL; Winther H; Issazadeh-Navikas S; Reinert LS; Holm CK
    Immunobiology; 2015 Jun; 220(6):762-8. PubMed ID: 25648689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKT-cell help to B lymphocytes can occur independently of cognate interaction.
    Tonti E; Galli G; Malzone C; Abrignani S; Casorati G; Dellabona P
    Blood; 2009 Jan; 113(2):370-6. PubMed ID: 18832653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
    Benlagha K; Weiss A; Beavis A; Teyton L; Bendelac A
    J Exp Med; 2000 Jun; 191(11):1895-903. PubMed ID: 10839805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
    Singh AK; Rhost S; Löfbom L; Cardell SL
    Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.
    Venkataswamy MM; Ng TW; Kharkwal SS; Carreño LJ; Johnson AJ; Kunnath-Velayudhan S; Liu Z; Bittman R; Jervis PJ; Cox LR; Besra GS; Wen X; Yuan W; Tsuji M; Li X; Ho DD; Chan J; Lee S; Frothingham R; Haynes BF; Panas MW; Gillard GO; Sixsmith JD; Korioth-Schmitz B; Schmitz JE; Larsen MH; Jacobs WR; Porcelli SA
    PLoS One; 2014; 9(9):e108383. PubMed ID: 25255287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.